Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process

Abstract

Polyglutamine (polyQ) diseases are a class of neurodegenerative disorders that cause cellular dysfunction and, eventually, neuronal death in specific regions of the brain. Neurodegeneration is linked to the misfolding and aggregation of expanded polyQ-containing proteins, and their inhibition is one of major therapeutic strategies used commonly. However, successful treatment has been limited to date because of the intrinsic properties of therapeutic agents (poor water solubility, low bioavailability, poor pharmacokinetic properties), and difficulty in crossing physiological barriers, including the blood-brain barrier (BBB). In order to solve these problems, nanoparticulate systems with dimensions of 1-1000 nm able to incorporate small and macromolecules with therapeutic value, to protect and deliver them directly to the brain, have recently been developed, but their use for targeting polyQ disease-mediated protein misfolding and aggregation remains scarce. This review provides an update of the polyQ protein aggregation process and the development of therapeutic strategies for halting it. The main features that a nanoparticulate system should possess in order to enhance brain delivery are discussed, as well as the different types of materials utilized to produce them. The final part of this review focuses on the potential application of nanoparticulate system strategies to improve the specific and efficient delivery of therapeutic agents to the brain for the treatment of polyQ diseases.

Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7

“…The therapeutic potential of many molecules remains unexplored, because of their intrinsic properties (poor water solubility, poor pharmacokinetic properties), and difficulty to penetrate the blood-brain barrier. There is thus a growing necessity of developing drug delivery system, such as nanoparticules, to improve target specificity and increase bioavailability of a drug in the brain [171,172].…”

Effect of UV and Gamma Irradiation Sterilization Processes in the Properties of Different Polymeric Nanoparticles for Biomedical Applications

“…They can incorporate multiple drugs and molecules into different tissues with high biocompatibility, biodegradability, low toxicity, and prolongation of release times [4,5]. Among others, poly-(ε-caprolactone) (PCL) and poly-(d,l-lactic-co-glycolic) acid (PLGA) are two of the most effective matrix agents for nanoparticles [6], that can be manufactured with different shapes and sizes with high reproducibility [7] and belong to the family of US Federal Drug Administration (FDA)-approved degradable polymers [8,9]. Depending on the material with which they are designed and the resulting physical and chemical characteristics, multiple nanoparticulate systems have been developed to be used as pharmacological vehicles or gene therapy vectors for several tissues such as central nervous system (CNS) delivery that can be made up of hydrophobic polymers such as poly(lactic acid) (PLA), PLGA, and PCL [4].…”

New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors

“…Despite the promissory future of the therapeutic drugs in the clinic of polyQ SCA diseases, some limitations need to be overcome before implementing clinical trials. For instance, virtually all these compounds exhibit poor physicochemical properties (solubility, permeability and metabolic stability), which in turn affect their ability to penetrate the blood–brain barrier (BBB) and exhibit central nervous system (CNS) activity [ 85 ].…”